Patents by Inventor Eri Arai
Eri Arai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11840738Abstract: A method for determining a risk of urothelial carcinoma may be based on the methylation level of DNA. A method for determining a risk of canceration of a urothelial tissue may involve detecting the DNA methylation level of a CpG site of at least one gene selected from TENM3, HOXC4, TLR1, CPVL and PRDM16 in genomic DNA preferably derived from a urothelial cell or a tissue containing the urothelial cell; and determining a risk of canceration of the urothelial tissue from the detected DNA methylation level.Type: GrantFiled: March 19, 2019Date of Patent: December 12, 2023Assignee: KEIO UNIVERSITYInventors: Yae Kanai, Eri Arai
-
Publication number: 20230175067Abstract: It is intended to provide a rapid, convenient, and highly accurate method for determining the prognosis of cancer. The present invention provides a method for determining a tissue having renal cell carcinoma, comprising: (1) subjecting sample DNA to ion exchange chromatography, wherein the sample DNA is obtained by treating target genomic DNA prepared from a renal tissue of a subject with bisulfite, followed by PCR amplification; (2) calculating a derivative value of a detection signal of the chromatography; and (3) determining the renal tissue as being a tissue having renal cell carcinoma having poor prognosis when the derivative value calculated in the step (2) has two or more maximums.Type: ApplicationFiled: July 14, 2022Publication date: June 8, 2023Applicants: NATIONAL CANCER CENTER, SEKISUI MEDICAL CO., LTD.Inventors: Yae KANAI, Eri ARAI, Yuriko KEMOTO, Takuya YOTANI
-
Publication number: 20230136481Abstract: A method may assess the risk of developing hepatocellular carcinoma from non-alcoholic steatohepatitis (NASH). Such a method may be for detecting hepatocytes or tissue including hepatocytes having a risk of developing hepatocellular carcinoma. The method may include detecting DNA methylation level of a target CpG site in genomic DNA derived from hepatocytes or tissue comprising hepatocytes with NASH, and detecting hepatocytes or tissue comprising hepatocytes having a risk of developing hepatocellular carcinoma, from the detected DNA methylation level.Type: ApplicationFiled: December 9, 2020Publication date: May 4, 2023Applicant: KEIO UNIVERSITYInventors: Yae KANAI, Eri ARAI, Junko KURAMOTO, Takuya YOTANI, Yuriko YAMADA
-
Publication number: 20230002832Abstract: Provided is a method for diagnosing upper urinary tract urothelial carcinoma with low invasiveness and high reliability. A method for identifying a cell or tissue having upper urinary tract urothelial carcinoma, comprising: detecting the DNA methylation level of at least one of specific CpG sites in genomic DNA derived from an upper urinary tract urothelial cell or a tissue containing the upper urinary tract urothelial cell; and determining whether the cell or tissue containing such a cell has upper urinary tract urothelial carcinoma on the basis of the detected DNA methylation level.Type: ApplicationFiled: November 27, 2020Publication date: January 5, 2023Applicant: KEIO UNIVERSITYInventors: Yae KANAI, Eri ARAI, Mao FUJIMOTO, Takuya YOTANI, Yuriko YAMADA
-
Publication number: 20220033911Abstract: Provided are a method for determining prognosis of endometrial cancer, a method for determining endometrial cancer patient compatible to preservation therapy, and a method for determining risk of endometrial cancer. The methods comprise detecting DNA methylation level at a target CpG site in a genomic DNA derived from an endometrial cell, endometrial cancer cell or tissue containing the cell. Prognosis of endometrial cancer, compatibility to preservation therapy, or risk of endometrial cancer of a subject is determined on the basis of the detected DNA methylation level.Type: ApplicationFiled: December 5, 2019Publication date: February 3, 2022Applicants: KEIO UNIVERSITY, SEKISUI MEDICAL CO., LTD.Inventors: Yae KANAI, Eri ARAI, Daisuke AOKI, Nobuyuki SUSUMU, Wataru YAMAGAMI, Takeshi MAKABE
-
Publication number: 20210404009Abstract: A method for determining a risk of urothelial carcinoma may be based on the methylation level of DNA. A method for determining a risk of canceration of a urothelial tissue may involve detecting the DNA methylation level of a CpG site of at least one gene selected from TENM3, HOXC4, TLR1, CPVL and PRDM16 in genomic DNA preferably derived from a urothelial cell or a tissue containing the urothelial cell; and determining a risk of canceration of the urothelial tissue from the detected DNA methylation level.Type: ApplicationFiled: March 19, 2019Publication date: December 30, 2021Applicant: KEIO UNIVERSITYInventors: Yae KANAI, Eri ARAI
-
Publication number: 20200216909Abstract: It is intended to provide highly sensitive and specific, rapid, and convenient method for evaluating a risk of hepatocellular carcinoma. The method for evaluating a risk of hepatocellular carcinoma comprises: (1) amplifying bisulfite-treated DNA derived from a liver tissue of a subject, wherein the DNA comprises a CpG site of an exon region of MGRN1 gene; (2) subjecting the obtained amplification product to ion exchange chromatography; and (3) determining whether or not the DNA is DNA obtained from a subject having a high risk of development of hepatocellular carcinoma on the basis of a peak shape of a detection signal of the chromatography.Type: ApplicationFiled: August 23, 2018Publication date: July 9, 2020Applicants: NATIONAL CANCER CENTER, SEKISUI MEDICAL CO., LTD.Inventors: Yae KANAI, Eri ARAI, Takuya YOTANI, Ei-ichiro SUNAMURA
-
Publication number: 20200199684Abstract: In order to provide a method for detecting an unfavorable prognostic risk of renal cell carcinoma easily with quite high sensitivity and specificity, a methylome analysis was performed on normal renal tissues, and non-cancerous tissues and renal cell carcinomas derived from patients with renal cell carcinomas. The result revealed that it was possible to detect an unfavorable prognostic risk of renal cell carcinoma by detecting a DNA methylation level at at least one CpG site of FAM150A, GRM6, ZNF540, ZFP42, ZNF154, RIMS4, PCDHAC1, KHDRBS2, ASCL2, KCNQ1, PRAC, WNT3A, TRH, FAM78A, ZNF671, SLC13A5, and NKX6-2 genes.Type: ApplicationFiled: December 10, 2019Publication date: June 25, 2020Applicant: NATIONAL CANCER CENTERInventors: Yae KANAI, Eri ARAI, Ying TIAN
-
Publication number: 20190360049Abstract: It is intended to provide a rapid, convenient, and highly accurate method for determining the prognosis of cancer. The present invention provides a method for determining a tissue having renal cell carcinoma, comprising: (1) subjecting sample DNA to ion exchange chromatography, wherein the sample DNA is obtained by treating target genomic DNA prepared from a renal tissue of a subject with bisulfite, followed by PCR amplification; (2) calculating a derivative value of a detection signal of the chromatography; and (3) determining the renal tissue as being a tissue having renal cell carcinoma having poor prognosis when the derivative value calculated in the step (2) has two or more maximums.Type: ApplicationFiled: September 2, 2016Publication date: November 28, 2019Applicants: NATIONAL CANCER CENTER, SEKISUI MEDICAL CO., LTD.Inventors: Yae KANAI, Eri ARAI, Yuriko NEMOTO, Takuya YOTANI
-
Patent number: 10190172Abstract: It is intended to provide a rapid, convenient, and highly accurate method for determining the prognosis of cancer. The present invention provides a method for determining the prognosis of a renal cell carcinoma patient, comprising: (1) treating genomic DNA prepared from a renal tissue of a subject with bisulfite; (2) amplifying the bisulfite-treated DNA by PCR; (3) subjecting the obtained PCR amplification product to ion exchange chromatography; (4) obtaining the retention time of a detection signal obtained by the chromatography; and (5) determining the renal cell carcinoma of the subject as having poor prognosis when the result of the step (4) is shorter than a retention time serving as a reference.Type: GrantFiled: March 2, 2015Date of Patent: January 29, 2019Assignees: NATIONAL CANCER CENTER, SEKISUI MEDICAL CO., LTD.Inventors: Yae Kanai, Eri Arai, Yuriko Nemoto, Takuya Yotani
-
Publication number: 20180340236Abstract: It is intended to provide a rapid, convenient, and highly accurate method for determining the prognosis of cancer. The present invention provides a method for determining the prognosis of a renal cell carcinoma patient, comprising: (1) treating genomic DNA prepared from a renal tissue of a subject with bisulfite; (2) amplifying the bisulfite-treated DNA by PCR; (3) subjecting the obtained PCR amplification product to ion exchange chromatography; (4) obtaining the retention time of a detection signal obtained by the chromatography; and (5) determining the renal cell carcinoma of the subject as having poor prognosis when the result of the step (4) is shorter than a retention time serving as a reference.Type: ApplicationFiled: June 5, 2018Publication date: November 29, 2018Applicants: NATIONAL CANCER CENTER, SEKISUI MEDICAL CO., LTD.Inventors: Yae KANAI, Eri ARAI, Yuriko NEMOTO, Takuya YOTANI
-
Publication number: 20170058355Abstract: It is intended to provide a rapid, convenient, and highly accurate method for determining the prognosis of cancer. The present invention provides a method for determining the prognosis of a renal cell carcinoma patient, comprising: (1) treating genomic DNA prepared from a renal tissue of a subject with bisulfite; (2) amplifying the bisulfite-treated DNA by PCR; (3) subjecting the obtained PCR amplification product to ion exchange chromatography; (4) obtaining the retention time of a detection signal obtained by the chromatography; and (5) determining the renal cell carcinoma of the subject as having poor prognosis when the result of the step (4) is shorter than a retention time serving as a reference.Type: ApplicationFiled: March 2, 2015Publication date: March 2, 2017Applicants: NATIONAL CANCER CENTER, SEKISUI MEDICAL CO., LTD.Inventors: Yae KANAI, Eri ARAI, Yuriko NEMOTO, Takuya YOTANI
-
Patent number: 9447472Abstract: The present invention aims at providing a method for assessing risk of hepatocellular carcinoma with high sensitivity and specificity. Extracted were 30 regions containing 45 CpG sites which have DNA methylation levels significantly different between in normal liver tissue samples and in noncancerous liver tissue samples from patients with hepatocellular carcinoma. It was found that the noncancerous liver tissue samples from patients with HCC were able to be assessed for risk of hepatocellular carcinoma by setting cutoff values for distinguishing between the normal liver tissue samples and the noncancerous liver tissue samples from patients with HCC for the extracted 30 regions.Type: GrantFiled: January 27, 2012Date of Patent: September 20, 2016Assignee: NATIONAL CANCER CENTERInventors: Yae Kanai, Eri Arai, Ryo Nagashio
-
Publication number: 20150118681Abstract: In order to provide a method for detecting an unfavorable prognostic risk of renal cell carcinoma easily with quite high sensitivity and specificity, a methylome analysis was performed on normal renal tissues, and non-cancerous tissues and renal cell carcinomas derived from patients with renal cell carcinomas. The result revealed that it was possible to detect an unfavorable prognostic risk of renal cell carcinoma by detecting a DNA methylation level at at least one CpG site of FAM150A, GRM6, ZNF540, ZFP42, ZNF154, RIMS4, PCDHAC1, KHDRBS2, ASCL2, KCNQ1, PRAC, WNT3A, TRH, FAM78A, ZNF671, SLC13A5, and NKX6-2 genes.Type: ApplicationFiled: April 30, 2013Publication date: April 30, 2015Applicant: NATIONAL CANCER CENTERInventors: Yae Kanai, Eri Arai, Ying Tian
-
Publication number: 20140017686Abstract: The present invention aims at providing a method for assessing risk of hepatocellular carcinoma with high sensitivity and specificity. Extracted were 30 regions containing 45 CpG sites which have DNA methylation levels significantly different between in normal liver tissue samples and in noncancerous liver tissue samples from patients with hepatocellular carcinoma. It was found that the noncancerous liver tissue samples from patients with HCC were able to be assessed for risk of hepatocellular carcinoma by setting cutoff values for distinguishing between the normal liver tissue samples and the noncancerous liver tissue samples from patients with HCC for the extracted 30 regions.Type: ApplicationFiled: January 27, 2012Publication date: January 16, 2014Applicant: NATIONAL CANCER CENTERInventors: Yae Kanai, Eri Arai, Ryo Nagashio